Atomoxetine Treatment in Adolescents with Attention-Deficit/Hyperactivity Disorder
Abstract
INTRODUCTION: This study compared two atomoxetine titration dosing schedules and two atomoxetine maintenance doses for treating adolescent attention-deficit/hyperactivity disorder (ADHD) inattention and hyperactivity/impulsivity. METHODS: Adolescents (N = 267) were randomized to a slow or fast titration schedule. Patients who responded continued on a 40-week maintenance treatment, randomized to either 0.8 or 1.4 mg/kg/day. RESULTS: During the acute period, significant benefit was demonstrated with both titration schedules on the ADHD Rating Scale total score. Although patients in both groups maintained benefit relative to week 0, statistically significant loss of benefit was found for patients maintained on 0.8 mg/kg/day but not on 1.4 mg/kg/day. A similar pattern was observed on the Clinical Global Impressions-ADHD-Severity scores and Life Participation Scale for ADHD-Child Version scores. Mean grades for most subjects improved for patients in both maintenance treatment groups although most improvements were not statistically significant. CONCLUSIONS: In adolescents with ADHD, treatment benefit at 8 weeks was better maintained long-term with 1.4 mg/kg/day than with 0.8 mg/kg/day. Improvement in adaptive functioning and age-appropriate developmental function was also demonstrated. Atomoxetine 0.8 and 1.4 mg/kg/day were equally well tolerated. CLINICAL TRIALS REGISTRY: Maintenance of benefit with atomoxetine hydrochloride in adolescents with ADHD, NCT00191035.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In adolescents, higher doses of atomoxetine have been associated with greater long-term efficacy.
“In adolescents, doses in the higher ranges have been associated with greater long-term efficacy [85].”
From Advances in understanding and treating ADHD (2011) · cites this paper as [85]
Cites
Young Adult Outcome of Hyperactive Children: Adaptive Functioning in Major Life Activities
Barkley, R. A., Fischer, M., Smallish, L., & Fletcher, K. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000189134.97436.e2 · Cited by 1,027 · see citing works
Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies
Michelson, D., Adler, L., Spencer, T., Reimherr, F. W., West, S. A., Allen, A. J., Kelsey, D., Wernicke, J., Dietrich, A., & Milton, D. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01671-2 · Cited by 790 · see citing works
Michelson, D., Faries, D., Wernicke, J., Kelsey, D., Kendrick, K., Sallee, F. R., Spencer, T., & the Atomoxetine ADHD Study Group (2001) · Pediatrics · doi:10.1542/peds.108.5.e83 · Cited by 666 · see citing works
Michelson, D., Allen, A. J., Busner, J., Casat, C., Dunn, D., Kratochvil, C., Newcorn, J., Sallee, F. R., Sangal, R. B., Saylor, K., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.11.1896 · Cited by 599 · see citing works
Kelsey, D. K., Sumner, C. R., Casat, C. D., Coury, D. L., Quintana, H., Saylor, K. E., Sutton, V. K., Gonzales, J., Malcolm, S. K., Schuh, K. J., et al. (2004) · Pediatrics · doi:10.1542/peds.114.1.e1 · Cited by 464 · see citing works
Self-citationSocial Functioning and Emotional Regulation in the Attention Deficit Hyperactivity Disorder Subtypes
Wheeler Maedgen, J., & Carlson, C. L. (2000) · Journal of Clinical Child Psychology · doi:10.1207/s15374424jccp2901_4 · Cited by 462 · see citing works
Barkley, R. A., Murphy, K. R., Dupaul, G. J., & Bush, T. (2002) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617702801345 · Cited by 387 · see citing works
Barkley, R. A., Murphy, K. R., & Kwasnik, D. (1996) · Pediatrics · doi:10.1542/peds.98.6.1089 · Cited by 375 · see citing works
Cigarette smoking in adult patients diagnosed with attention deficit hyperactivity disorder
Pomerleau, O. F., Downey, K. K., Stelson, F. W., & Pomerleau, C. S. (1995) · Journal of Substance Abuse · doi:10.1016/0899-3289(95)90030-6 · Cited by 349 · see citing works
Kessler, R. C., Adler, L., Ames, M., Barkley, R. A., Birnbaum, H., Greenberg, P., Johnston, J. A., Spencer, T., & ??st??n, T. B. (2005) · Journal of Occupational and Environmental Medicine · doi:10.1097/01.jom.0000166863.33541.39 · Cited by 335 · see citing works
Spencer, T., Heiligenstein, J. H., Biederman, J., Faries, D. E., Kratochvil, C. J., Conners, C. K., & Potter, W. Z. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1209 · Cited by 333 · cited 1× · see citing works
“Numerous clinical trials have demonstrated the efficacy and safety of atomoxetine for treating ADHD (Michelson et al. 2001; Michelson et al. 2003; Michelson et al. 2002; Spencer et al. 2002; Kelsey et al. 2004; Allen et al. 2005).”
Biederman, J., Wilens, T. E., Mick, E., Faraone, S. V., & Spencer, T. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(97)00406-x · Cited by 315 · see citing works
Michelson, D., Buitelaar, J. K., Danckaerts, M., Gillberg, C., Spencer, T. J., Zuddas, A., Faries, D. E., Zhang, S., & Biederman, J. (2004) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000125089.35109.81 · Cited by 307 · see citing works
Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders
Allen, A. J., Kurlan, R. M., Gilbert, D. L., Coffey, B. J., Linder, S. L., Lewis, D. W., Winner, P. K., Dunn, D. W., Dure, L. S., Sallee, F. R., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000188869.58300.a7 · Cited by 225 · see citing works
Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder
Wilens, T. E., Newcorn, J. H., Kratochvil, C. J., Gao, H., Thomason, C. K., Rogers, A. K., Feldman, P. D., & Levine, L. R. (2006) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2006.01.052 · Cited by 102 · cited 1× · see citing works
“Several clinical studies have demonstrated the benefit of ato-moxetine maintenance therapy (Buitelaar et al. 2007; Hazell et al. 2006; Michelson et al. 2004; Newcorn et al. 2006; Wilens et al. 2006).”
Buitelaar, J. K., Michelson, D., Danckaerts, M., Gillberg, C., Spencer, T. J., Zuddas, A., Faries, D. E., Zhang, S., & Biederman, J. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.03.066 · Cited by 85 · see citing works
Hazell, P., Zhang, S., Wolańczyk, T., Barton, J., Johnson, M., Zuddas, A., Danckaerts, M., Ladikos, A., Benn, D., Yoran‐Hegesh, R., et al. (2006) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-006-0506-y · Cited by 73 · see citing works
Low-Dose Atomoxetine for Maintenance Treatment of Attention-Deficit/Hyperactivity Disorder
Newcorn, J. H., Michelson, D., Kratochvil, C. J., Allen, A. J., Ruff, D. D., Moore, R. J., & for the Atomoxetine Low-dose Study Group (2006) · PEDIATRICS · doi:10.1542/peds.2005-2999 · Cited by 34 · see citing works
Saylor, K. E., Buermeyer, C. M., Sutton, V. K., Faries, D. E., Khan, S., & Schuh, K. J. (2007) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2007.0030 · Cited by 19 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Advances in understanding and treating ADHD
Antshel, K. M., Hargrave, T. M., Simonescu, M., Kaul, P., Hendricks, K., & Faraone, S. V. (2011) · BMC Medicine · doi:10.1186/1741-7015-9-72 · Cited by 140 · see citing works
van de Loo-Neus, G. H. H., Rommelse, N., & Buitelaar, J. K. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.03.008 · Cited by 98 · see citing works
- Authors
- Wietecha, L. A., Williams, D. W., Herbert, M., Melmed, R. D., Greenbaum, M., & Schuh, K.
- Affiliations
- Eli Lilly (United States) (US)
- Utah Personnel Development Center, Salt Lake City, UT.
- Melmed Center, Scottsdale, AZ.
- Reprogenetics (US)
- Corresponding author
- Wietecha, Linda A.
- Venue
- Journal of Child and Adolescent Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2009-12
- Volume
- 19
- Issue
- 6
- Pages
- 719-730
- ISSN
- 1044-5463 (ISSN-L)
- 1557-8992
- OpenAlex
- W2086807967
- Cited by
- 21
- References
- 19
- Citations by year
- 2019: 1 · 2017: 2 · 2016: 3 · 2015: 3 · 2014: 3 · 2013: 1 · 2012: 2
- FWCI
- 1.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Child and Adolescent Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Social Sciences › Psychology › Neuropsychology and Physiological Psychology › Developmental and Educational Neuropsychology
- Keywords
- atomoxetine, attention deficit hyperactivity disorder, adolescents, dose titration, maintenance dose, inattention, hyperactivity/impulsivity, treatment response maintenance, adaptive behavior, drug tolerability
- MeSH terms
- Atomoxetine Hydrochloride, Adaptation, Psychological, Adolescent, Adolescent Behavior, Attention Deficit Disorder with Hyperactivity, Dose-Response Relationship, Drug, Drug Administration Schedule, Educational Status, Female, Humans, Male, Propylamines, Psychiatric Status Rating Scales, Severity of Illness Index, Treatment Outcome, Adrenergic Uptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
